Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials

Journal of Clinical Psychiatry

Volumn 71, Issue 11, 2010, Pages 1425-1433

  Seemüller, Florian ^a   Möller, Hans Jürgen ^a   Obermeier, Michael ^a   Adli, Mazda ^b   Bauer, Michael ^c   Kronmüller, Klaus ^d   Holsboer, Florian ^e   Brieger, Peter ^f   Laux, Gerd ^g   Bender, Wolfram ^h   Heuser, Isabella ^b   Zeiler, Joachim ⁱ   Gaebel, Wolfgang ^j   Schennach Wolff, Rebecca ^a   Henkel, Verena ^a   Riedel, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g Inn Salzach Hospital   (Germany)

^h KLINIKUM MÜNCHEN OST   (Germany)

ⁱ Vivantes Auguste Viktoria Klinikum   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649776463     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05166blu     Document Type: Article

References (33)

1. Guyatt GH, Rennie D. Users' guides to the medical literature. JAMA. 1993;270(17):2096-2097.
2. Riedel M, Strassnig M, Müller N, et al. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci. 2005;255(2):143-148.
3. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473.
4. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159(2):191-200. doi:10.176/api.ajp.159.2.191 PubMed (Pubitemid 34126894)
5. Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007;27(3):295-301.
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
7. Wittchen HU, Wunderlich U, Gruschwitz S, et al. Strukturiertes Klinisches Interview für DSM-IV. Göttingen, Germany: Hogrefe; 1997.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
9. Cording C, Gaebel W, Spengler A. Die neue psychiatrische Basisdokumentation. eine empfehlung der DGPPN zur qualitätssicherung im (teil-) stationären bereich. [The new psychiatric basic documentation. a recommendation by the DGPPN for quality assurance in inpatient treatment] Spektrum Psychiatrie Nervenheilkunde. 1995;24:3-41.
10. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56(10):968-976.
11. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;76(s334):1-100. doi:10.1/j.160-047.1987.tb1056.x PubMed
12. Möller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. Eur Arch Psychiatry Clin Neurosci. 2006;256(6):329-343.
13. Bauer M, Bschor T, Pfennig A, et al. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8(2):67-104.
14. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Am J Psychiatry. 2000;157:1-45.
15. Deutsche Gesellschaft für Psychiatrie PuN. Praxisleitlinien in Psychiatrie und Psychotherapie, 5: Behandlungsleitlinien affektive Erkrankungen. [Practice Guideline for the Treatment of Affective Disorders]. Darmstadt, Germany: Steinkopff; 2000.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
18. Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(8):1276-1280.
19. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370-1372.
20. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? a STAR*D report. Am J Psychiatry. 2009;166(5):599-607.
21. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002;27(4):250-257.
22. Deykin EY, DiMascio A. Relationship of patient background characteristics to efficacy of pharmacotherapy in depression. J Nerv Ment Dis. 1972;155(3):209-215.
23. Paykel ES, Prusoff BA, Klerman GL, et al. Clinical response to amitriptyline among depressed women. J Nerv Ment Dis. 1973;156(3):149-165.
24. Rickels K, Gordon PE, Weise CC, et al. Amitriptyline and trimipramine in neurotic depressed outpatients: a collaborative study. Am J Psychiatry. 1970;127(2):208-218.
25. Raskin A, Crook TH. The endogenous - neurotic distinction as a predictor of response to antidepressant drugs. Psychol Med. 1976;6(1):59-70.
26. Paykel ES. Depressive typologies and response to amitriptyline. Br J Psychiatry. 1972;120(555):147-156.
27. Burt CG, Gordon WF, Holt NF, et al. Amitriptyline in depressive states: a controlled trial. J Ment Sci. 1962;108:711-730.
28. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
29. Serretti A, Olgiati P, Liebman MN, et al. Clinical prediction of antidepressant response in mood disorders: linear multivariate vs neural network models. Psychiatry Res. 2007;152(2-3):223-231. doi:10.1016/j.psychres.206.07.09 PubMed (Pubitemid 47212479)
30. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53(3):232-240.
31. Roy-Byrne PP, Pages KP, Russo JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20(2):129-136.
32. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189(2):124-131.
33. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-1547. doi:10.176/api.ajp.161.9.1537 PubMed (Pubitemid 39201448)